Arnhold LLC Lowers Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Arnhold LLC lowered its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 1.2% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 22,952 shares of the biopharmaceutical company’s stock after selling 279 shares during the period. Arnhold LLC’s holdings in Gilead Sciences were worth $1,859,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the business. Tompkins Financial Corp boosted its holdings in Gilead Sciences by 223.1% in the third quarter. Tompkins Financial Corp now owns 349 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 241 shares during the period. OFI Invest Asset Management acquired a new stake in shares of Gilead Sciences in the third quarter valued at approximately $26,000. Fortitude Family Office LLC purchased a new position in shares of Gilead Sciences during the fourth quarter worth approximately $29,000. Rakuten Securities Inc. acquired a new position in shares of Gilead Sciences in the 4th quarter valued at $33,000. Finally, Financial Connections Group Inc. purchased a new stake in Gilead Sciences in the 4th quarter valued at $40,000. 83.67% of the stock is owned by hedge funds and other institutional investors.

Gilead Sciences Price Performance

GILD stock traded down $0.74 on Tuesday, reaching $65.20. The company had a trading volume of 7,433,077 shares, compared to its average volume of 7,480,851. The company has a debt-to-equity ratio of 1.08, a quick ratio of 0.72 and a current ratio of 0.98. The company’s fifty day moving average is $71.03 and its 200 day moving average is $76.08. The company has a market cap of $81.18 billion, a P/E ratio of 181.11, a PEG ratio of 1.29 and a beta of 0.19. Gilead Sciences, Inc. has a 1 year low of $64.63 and a 1 year high of $87.86.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($1.32) EPS for the quarter, topping analysts’ consensus estimates of ($1.49) by $0.17. The firm had revenue of $6.69 billion during the quarter, compared to analysts’ expectations of $6.36 billion. Gilead Sciences had a return on equity of 24.34% and a net margin of 1.76%. The firm’s quarterly revenue was up 5.3% compared to the same quarter last year. During the same quarter last year, the business posted $1.37 EPS. On average, research analysts forecast that Gilead Sciences, Inc. will post 3.82 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, June 27th. Shareholders of record on Friday, June 14th will be paid a dividend of $0.77 per share. This represents a $3.08 dividend on an annualized basis and a dividend yield of 4.72%. The ex-dividend date is Friday, June 14th. Gilead Sciences’s dividend payout ratio is presently 855.56%.

Analysts Set New Price Targets

GILD has been the topic of a number of recent research reports. Truist Financial lowered shares of Gilead Sciences from a “buy” rating to a “hold” rating and dropped their price objective for the company from $91.00 to $82.00 in a research note on Thursday, February 22nd. Barclays decreased their price objective on Gilead Sciences from $80.00 to $76.00 and set an “equal weight” rating for the company in a research report on Monday. Morgan Stanley dropped their target price on Gilead Sciences from $80.00 to $78.00 and set an “equal weight” rating on the stock in a report on Friday. HSBC raised Gilead Sciences from a “reduce” rating to a “hold” rating and set a $69.00 price target for the company in a report on Wednesday, April 24th. Finally, StockNews.com upgraded shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Eleven analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $83.60.

Insider Activity

In other news, insider Merdad Parsey sold 2,000 shares of the stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $72.96, for a total transaction of $145,920.00. Following the transaction, the insider now directly owns 96,304 shares in the company, valued at approximately $7,026,339.84. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Company insiders own 0.29% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.